Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946521 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL31321063 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL8330074 | 0.93 | ITGB3 (0.87) | ITGB3ITGAVITGA2B | |
| SCHEMBL8325096 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL8327554 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL13936150 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL7918275 | 0.91 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| SCHEMBL7074204 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7072095 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7365226 | 0.89 | ITGB3 (0.80) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435967-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | claimed |
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | claimed |
| EP-1317270-A1 | EXEMESTANE FOR THE TREATMENT OF OESTROGEN-DEPENDENT CANCERS | Pharmacia Italia S.p.A. (IT) | 2003-06-11 | — | — | EP | claimed |
| WO-2003032961-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | PHARMACIA ITALIA SPA (IT) | 2003-04-24 | — | — | WO | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| WO-2002020020-A1 | EXEMESTANE AS CHEMOPREVENTING AGENT | PHARMACIA ITALIA S.P.A. (IT) | 2002-03-14 | — | — | WO | claimed |
| EP-1140177-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038715-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | claimed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | CYP19A1, BRCA1, ESR2 | ITGB3 918/4885ITGAV 2117/4885ITGA2B 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.